Friday May 4 | Theflyonthewall.com
Columbia Laboratories evaluating potential strategic transactions
Columbia has streamlined the organization to operate as cash flow neutral-to-positive, while maintaining its significant upside potential from milestone payments and royalties if Watson is successful in gaining FDA approval and commercializing a progesterone product for the preterm birth indication.